178 related articles for article (PubMed ID: 19747570)
1. Enhanced immunogenicity and cross-reactivity of HIV-1 V3-peptide and multiple antigen peptides conjugated to distinct carrier proteins.
Cruz LJ; Cabrales A; Iglesias E; Aguilar JC; González LJ; Reyes O
Int Immunopharmacol; 2009 Nov; 9(12):1452-9. PubMed ID: 19747570
[TBL] [Abstract][Full Text] [Related]
2. Broader cross-reactivity after conjugation of V3 based multiple antigen peptides to HBsAg.
Iglesias E; Aguilar JC; Cruz LJ; Reyes O
Mol Immunol; 2005 Jan; 42(1):99-104. PubMed ID: 15488948
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity comparison of a multi-antigenic peptide bearing V3 sequences of the human immunodeficiency virus type 1 with TAB9 protein in mice.
Cruz LJ; Quintana D; Iglesias E; Garcia Y; Huerta V; Garay HE; Duarte C; Reyes O
J Pept Sci; 2000 May; 6(5):217-24. PubMed ID: 10823490
[TBL] [Abstract][Full Text] [Related]
4. Different immune response of mice immunized with conjugates containing multiple copies of either consensus or mixotope versions of the V3 loop peptide from human immunodeficiency virus type 1.
Cruz LJ; Iglesias E; Aguilar JC; Cabrales A; Reyes O; Andreu D
Bioconjug Chem; 2004; 15(5):1110-7. PubMed ID: 15366967
[TBL] [Abstract][Full Text] [Related]
5. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
6. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of different presentation strategies for an HIV peptide immunogen.
Cruz LJ; Iglesias E; Aguilar JC; González LJ; Reyes O; Albericio F; Andreu D
Bioconjug Chem; 2004; 15(1):112-20. PubMed ID: 14733590
[TBL] [Abstract][Full Text] [Related]
8. A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian and Swedish HIV-1-positive sera.
Blomberg J; Lawoko A; Pipkorn R; Moyo S; Malmvall BE; Shao J; Dash R; Tswana S
AIDS; 1993 Jun; 7(6):759-67. PubMed ID: 8363754
[TBL] [Abstract][Full Text] [Related]
9. Improved humoral and cellular immune responses against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted into the hepatitis B surface antigen.
Fomsgaard A; Nielsen HV; Bryder K; Nielsen C; Machuca R; Bruun L; Hansen J; Buus S
Scand J Immunol; 1998 Apr; 47(4):289-95. PubMed ID: 9600309
[TBL] [Abstract][Full Text] [Related]
10. Antigenicity and predefined specificities of the multi-epitope vaccine in candidate consisting of neutralizing epitope and mutated epitopes suggested a new way against HIV-1 mutation.
Tian H; Xiao Y; Qin L; Chen YH
Immunobiology; 2001 Dec; 204(4):434-41. PubMed ID: 11776398
[TBL] [Abstract][Full Text] [Related]
11. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
[TBL] [Abstract][Full Text] [Related]
12. A combinatorial peptide library around variation of the human immunodeficiency virus (HIV-1) V3 domain leads to distinct T helper cell responses.
Estaquier J; Boutillon C; Georges B; Ameisen JC; Tartar A; Auriault C
J Pept Sci; 1996; 2(3):165-75. PubMed ID: 9231325
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of a vaccine preparation representing the variable regions of the HIV type 1 envelope glycoprotein.
Carlos MP; Anderson DE; Gardner MB; Torres JV
AIDS Res Hum Retroviruses; 2000 Jan; 16(2):153-61. PubMed ID: 10659054
[TBL] [Abstract][Full Text] [Related]
14. Impact of epitope permutations in the antibody response of mice to a multi-epitope polypeptide of the V3 loop of human immunodeficiency virus type 1.
Aguilar A; Carrazana Y; Duarte CA
Biomol Eng; 2001 Oct; 18(3):117-24. PubMed ID: 11566603
[TBL] [Abstract][Full Text] [Related]
15. A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120.
Greenstein JL; Schad VC; Goodwin WH; Brauer AB; Bollinger BK; Chin RD; Kuo MC
J Immunol; 1992 Jun; 148(12):3970-7. PubMed ID: 1376346
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of epitope-specific cellular immune responses by immunization with HIV-1 peptides genetically conjugated to the B-subunit of recombinant cholera toxin.
Boberg A; Gaunitz S; Bråve A; Wahren B; Carlin N
Vaccine; 2008 Sep; 26(40):5079-82. PubMed ID: 18514370
[TBL] [Abstract][Full Text] [Related]
17. Antigenicity and immunogenicity of the V3 domain of HIV type 1 glycoprotein 120 expressed on the surface of Streptococcus gordonii.
Oggioni MR; Medaglini D; Romano L; Peruzzi F; Maggi T; Lozzi L; Bracci L; Zazzi M; Manca F; Valensin PE; Pozzi G
AIDS Res Hum Retroviruses; 1999 Mar; 15(5):451-9. PubMed ID: 10195755
[TBL] [Abstract][Full Text] [Related]
18. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
Bower JF; Green TD; Ross TM
Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
[TBL] [Abstract][Full Text] [Related]
19. Assembly, structure, and antigenic properties of virus-like particles rich in HIV-1 envelope gp120.
Berkower I; Raymond M; Muller J; Spadaccini A; Aberdeen A
Virology; 2004 Mar; 321(1):75-86. PubMed ID: 15033567
[TBL] [Abstract][Full Text] [Related]
20. Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection.
Okuda K; Kaneko T; Yamakawa T; Tanaka S; Shigematsu T; Yamamoto A; Hamajima K; Nakajima K; Kawamoto S; Phanuphak P
J Mol Recognit; 1993 Sep; 6(3):101-9. PubMed ID: 8060667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
